335 related articles for article (PubMed ID: 30771218)
21. Access to Tyrosine Kinase Inhibitors and Survival in Patients with Advanced EGFR
Goulart BHL; Chennupati S; Fedorenko CR; Ramsey SD
Clin Lung Cancer; 2021 Sep; 22(5):e723-e733. PubMed ID: 33685820
[TBL] [Abstract][Full Text] [Related]
22. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
Chang GC; Tseng CH; Hsu KH; Yu CJ; Yang CT; Chen KC; Yang TY; Tseng JS; Liu CY; Liao WY; Hsia TC; Tu CY; Lin MC; Tsai YH; Hsieh MJ; Wu WS; Chen YM
Lung Cancer; 2017 Feb; 104():58-64. PubMed ID: 28213001
[TBL] [Abstract][Full Text] [Related]
23. [Timing of Whole Brain Radiotherapy on Survival of Patients with EGFR-mutated
Non-small Cell Lung Cancer and Brain Metastases].
Liu G; Zhang X; Tian C; Xia G; Liu P; Zhang Q; Li X; Zhang H; Qin N; Wang J; Zhang S
Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):501-7. PubMed ID: 27561798
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: a real-world study.
Wei H; Zhou X; Yang H; Gong Y; Wang J; Xu Y; Zhou L; Xue J; Zou B; Zhang Y; Zhu J; Peng F; Huang M; Lu Y; Liu Y
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2589-2598. PubMed ID: 34669037
[TBL] [Abstract][Full Text] [Related]
25. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.
Byeon S; Ham JS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Med Oncol; 2016 Aug; 33(8):97. PubMed ID: 27447711
[TBL] [Abstract][Full Text] [Related]
26. SBRT for oligoprogressive oncogene addicted NSCLC.
Basler L; Kroeze SG; Guckenberger M
Lung Cancer; 2017 Apr; 106():50-57. PubMed ID: 28285694
[TBL] [Abstract][Full Text] [Related]
27. Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment.
Ni Y; Ye X; Yang X; Huang G; Li W; Wang J; Han X; Wei Z; Meng M
J Cancer Res Clin Oncol; 2020 Jan; 146(1):197-203. PubMed ID: 31599340
[TBL] [Abstract][Full Text] [Related]
28. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
Gainor JF; Shaw AT; Sequist LV; Fu X; Azzoli CG; Piotrowska Z; Huynh TG; Zhao L; Fulton L; Schultz KR; Howe E; Farago AF; Sullivan RJ; Stone JR; Digumarthy S; Moran T; Hata AN; Yagi Y; Yeap BY; Engelman JA; Mino-Kenudson M
Clin Cancer Res; 2016 Sep; 22(18):4585-93. PubMed ID: 27225694
[TBL] [Abstract][Full Text] [Related]
29. Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study.
Auliac JB; Fournier C; Audigier Valette C; Perol M; Bizieux A; Vinas F; Decroisette Phan van Ho C; Bota Ouchlif S; Corre R; Le Garff G; Fournel P; Baize N; Lamy R; Vergnenegre A; Arpin D; Marin B; Chouaid C; Gervais R
Target Oncol; 2016 Apr; 11(2):167-74. PubMed ID: 26315967
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with recurrent non-small cell lung cancer after definitive concurrent chemoradiation or radiotherapy.
Hyung J; Yoon H; Choi CM; Yoon S; Lee DH; Kim SW; Kim HR; Kim SS; Song SY; Lee JC
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4243-4251. PubMed ID: 36064984
[TBL] [Abstract][Full Text] [Related]
31. Brain metastases from non-small cell lung cancer with EGFR or ALK mutations: A systematic review and meta-analysis of multidisciplinary approaches.
Singh R; Lehrer EJ; Ko S; Peterson J; Lou Y; Porter AB; Kotecha R; Brown PD; Zaorsky NG; Trifiletti DM
Radiother Oncol; 2020 Mar; 144():165-179. PubMed ID: 31812932
[TBL] [Abstract][Full Text] [Related]
32. Local Thermal Ablation with Continuous EGFR Tyrosine Kinase Inhibitors for EGFR-Mutant Non-small Cell Lung Cancers that Developed Extra-Central Nervous System (CNS) Oligoprogressive Disease.
Ni Y; Liu B; Ye X; Fan W; Bi J; Yang X; Huang G; Li W; Wang J; Han X; Wei Z; Meng M
Cardiovasc Intervent Radiol; 2019 May; 42(5):693-699. PubMed ID: 30701290
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases.
Ke SB; Qiu H; Chen JM; Shi W; Chen YS
Curr Med Sci; 2018 Dec; 38(6):1062-1068. PubMed ID: 30536070
[TBL] [Abstract][Full Text] [Related]
34. Intracranial disease control for EGFR-mutant and ALK-rearranged lung cancer with large volume or symptomatic brain metastases.
Dutta SW; Mack ML; Aliotta E; Ward KA; Muller DA; Larner JM; Fadul CE; Hall RD; Gentzler RD; Sheehan JP
J Neurooncol; 2020 Sep; 149(2):357-366. PubMed ID: 32902767
[TBL] [Abstract][Full Text] [Related]
35. Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study.
Schuette W; Schirmacher P; Eberhardt WEE; Dietel M; Zirrgiebel U; Muehlenhoff L; Thomas M
BMC Cancer; 2018 Feb; 18(1):135. PubMed ID: 29402243
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.
Lee VH; Leung DK; Choy TS; Lam KO; Lam PM; Leung TW; Kwong DL
BMC Cancer; 2016 Feb; 16():147. PubMed ID: 26911310
[TBL] [Abstract][Full Text] [Related]
37. Beyond disease-progression: Clinical outcomes after EGFR-TKIs in a cohort of EGFR mutated NSCLC patients.
Tudor RA; D'Silva A; Tremblay A; MacEachern P; Morris D; Brenner D; Kopciuk K; Bebb DG
PLoS One; 2017; 12(8):e0181867. PubMed ID: 28777825
[TBL] [Abstract][Full Text] [Related]
38. Clinical Characteristics and Continued Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Administration in EGFR-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis.
Hong SH; Kim YS; Lee JE; Kim IH; Kim SJ; Han D; Yoo IeR; Chung YG; Kim YH; Lee KY; Kang JH
Cancer Res Treat; 2016 Jul; 48(3):1110-9. PubMed ID: 26790969
[TBL] [Abstract][Full Text] [Related]
39. Effect of timing, technique and molecular features on brain control with local therapies in oncogene-driven lung cancer.
El Shafie RA; Seidensaal K; Bozorgmehr F; Kazdal D; Eichkorn T; Elshiaty M; Weber D; Allgäuer M; König L; Lang K; Forster T; Arians N; Rieken S; Heussel CP; Herth FJ; Thomas M; Stenzinger A; Debus J; Christopoulos P
ESMO Open; 2021 Jun; 6(3):100161. PubMed ID: 34090172
[TBL] [Abstract][Full Text] [Related]
40. Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.
Lin JJ; Cardarella S; Lydon CA; Dahlberg SE; Jackman DM; Jänne PA; Johnson BE
J Thorac Oncol; 2016 Apr; 11(4):556-65. PubMed ID: 26724471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
